If you're interested in the biopharma sector I would highly recommend checking out Alpha Cognition Inc. ( $ACOG.V ACOGF ).
$ACOG is a biopharmaceutical company that is in clinical stages for developing treatments for under-served neurodegenerative diseases, like Alzheimer's Disease and ALS.
In a recent interview $ACOG's CEO, Michael McFadden, described the company's two drugs, ALPHA-1062 and ALPHA-602.
He said that Alpha-1062 is a pro-drug of a drug that was developed by J&J and approved in the mid-2000s. J&J's version of the drug had several harsh side effects, however, $ACOG's version is optimized to minimize side effects.
He describes Alpha-602 as a "pro granulin gene therapy. That is a full link pro granulin, pro granulin is a protein chain and that drug has shown applicability for a number of disease states." Additionally, McFadden says that Alpha-602 could possibly become a curative option for ALS.
On financing, McFadden says that the $14.4M that the company gained from their Canadian IPO will be used for the commercialization of their drugs.
If you think that $ACOG and the drugs they are developing seem promising, I would highly recommend looking into them and this interview is a great place to start:
https://stockhouse.com/opinion/inte...-876e-75e8710c4199&utm_content=&utm_campaign=
Currently $ACOG is trading at $1.29 (down 3% today), with a $79.33M market cap.
$ACOG is a biopharmaceutical company that is in clinical stages for developing treatments for under-served neurodegenerative diseases, like Alzheimer's Disease and ALS.
In a recent interview $ACOG's CEO, Michael McFadden, described the company's two drugs, ALPHA-1062 and ALPHA-602.
He said that Alpha-1062 is a pro-drug of a drug that was developed by J&J and approved in the mid-2000s. J&J's version of the drug had several harsh side effects, however, $ACOG's version is optimized to minimize side effects.
He describes Alpha-602 as a "pro granulin gene therapy. That is a full link pro granulin, pro granulin is a protein chain and that drug has shown applicability for a number of disease states." Additionally, McFadden says that Alpha-602 could possibly become a curative option for ALS.
On financing, McFadden says that the $14.4M that the company gained from their Canadian IPO will be used for the commercialization of their drugs.
If you think that $ACOG and the drugs they are developing seem promising, I would highly recommend looking into them and this interview is a great place to start:
https://stockhouse.com/opinion/inte...-876e-75e8710c4199&utm_content=&utm_campaign=
Currently $ACOG is trading at $1.29 (down 3% today), with a $79.33M market cap.